SCHEMBL122186

SCHEMBL122186

CCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](OC(=O)CC)C[C@@]21C

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 8/20 0.79
PGR P06401 5/20 0.79
NR3C1 P04150 5/20 0.79
HIF1A Q16665 6/20 0.73
KMT2A Q03164 3/20 0.73
AR P10275 3/20 0.67
CHRM1 P11229 1/20 0.61
CYP3A4 P08684 4/20 0.53
MAPT P10636 3/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
NR1I2 O75469 2/20 0.53
LMNA P02545 2/20 0.53
HPGD P15428 1/20 0.53
MEN1 O00255 1/20 0.53
MLNR O43193 1/20 0.53
ADORA3 P0DMS8 1/20 0.53
HTT P42858 1/20 0.53
SLC6A3 Q01959 1/20 0.53
PDE4D Q08499 1/20 0.53
PDE3A Q14432 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL110284 0.93 NR3C2 (0.69) NR3C2PGRNR3C1HIF1AKMT2A
SCHEMBL1807730 0.92 PGR (0.68) NR3C2PGRNR3C1HIF1AKMT2A
SCHEMBL1807731 0.91 PGR (0.70) NR3C2PGRNR3C1HIF1AKMT2A
SCHEMBL23456329 0.90 NR3C2 (0.70) NR3C2PGRNR3C1HIF1AKMT2A
Hydrocortisone Butyrate SCHEMBL14936050 0.89 NR3C2 (1.00) NR3C2PGRNR3C1HIF1AKMT2A
Hydrocortisone Butyrate SCHEMBL21111521 0.89 NR3C2 (1.00) NR3C2PGRNR3C1HIF1AKMT2A
Hydrocortisone Butyrate SCHEMBL14339600 0.89 NR3C2 (1.00) NR3C2PGRNR3C1HIF1AKMT2A
Hydrocortisone Butyrate SCHEMBL111478 0.89 NR3C2 (1.00) NR3C2PGRNR3C1HIF1AKMT2A
Hydrocortisone Butyrate SCHEMBL14473210 0.89 NR3C2 (1.00) NR3C2PGRNR3C1HIF1AKMT2A
Hydrocortisone Butyrate SCHEMBL4695 0.89 NR3C2 (1.00) NR3C2PGRNR3C1HIF1AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 585 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4744657-A1 THERAPEUTIC AGENT FOR HUMAN GRAFT VERSUS HOST DISEASE AND COMBINATION THEREOF National University Corporation Okayama University (JP) 2026-05-20 EP claimed
WO-2023160631-A1 NANO PREPARATION FOR JOINT ANALGESIA, AND PREPARATION METHOD THEREFOR AND USE THEREOF 中南大学湘雅医院 2023-08-31 WO claimed
CN-116077465-A Nanometer preparation for joint pain relief, and preparation method and application thereof 中南大学湘雅医院 2023-05-09 CN claimed
US-11376262-B2 Method of treating an inflammatory or infectious disease ACTIVUS PHARMA CO., LTD. (JP) 2022-07-05 US claimed
CN-111529684-A Use of oral sustained release compositions containing cyclosporin 卓越治疗有限公司 2020-08-14 CN claimed
US-20200129526-A1 METHOD OF TREATING AN INFLAMMATORY OR INFECTIOUS DISEASE FORMOSA PHARMACEUTICALS, INC. (TW) 2020-04-30 US claimed
CN-110945016-A Peptide compounds, conjugate compounds and uses thereof for the treatment of inflammatory diseases 特拉斯福特普拉斯公司 2020-03-31 CN claimed
US-10588913-B2 Aqueous suspension agent containing glucocorticosteroid nanoparticles ACTIVUS PHARMA CO., LTD. (JP) 2020-03-17 US claimed
US-20180117064-A1 AQUEOUS SUSPENSION AGENT CONTAINING GLUCOCORTICOSTEROID NANOPARTICLES FORMOSA PHARMACEUTICALS, INC. (TW) 2018-05-03 US claimed
EP-3295943-A1 AQUEOUS SUSPENSION AGENT COMPRISING GLUCOCORTICOSTEROID NANOPARTICLES Activus Pharma Co., Ltd. (JP) 2018-03-21 EP claimed
EP-2050439-B1 PROCESS FOR PRODUCTION OF SPHERICAL GRANULE CONTAINING SLIGHTLY WATER-SOLUBLE SUBSTANCE ASAHI CHEMICAL IND (JP) 2016-11-23 EP claimed
US-9095512-B2 Method for producing spherical base granules comprising hardly water-soluble drug ASAHI KASEI CHEMICALS CORPORATION (JP) 2015-08-04 US claimed
US-20090012051-A1 EXTERNAL PREPARATION KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-01-08 US claimed
US-20070287689-A1 Therapeutic And/Or Preventive Agents For Chronic Skin Diseases KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-12-13 US claimed
EP-1810692-A1 REMEDIES/PREVENTIVES FOR CHRONIC SKIN DISEASE KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-07-25 EP claimed
WO-1997027862-A1 SUPPLEMENTATION OF GLUCOCORTICOIDS BELLARA MEDICAL PRODUCTS LIMITED (AU) 1997-08-07 WO claimed
US-4794107-A HYDROCORTISONE BUTYRATE PROPIONATE, PROPYLENE GLYCOL, SURFACTANTS, PARAFIN HYDROCARBONS; ANTIINFLAMMATORY AGENTS TAISHO PHARMACEUTICAL CO., LTD. (JP) 1988-12-27 US claimed
US-4794106-A HYDROCORTISONE BUTYRATE PROPIONATE, HIGHER PARAFFINIC HYDROCARBON, SURFACTANT TAISHO PHARMACEUTICAL CO., LTD. (JP) 1988-12-27 US claimed
JP-61167614-A None JP disclosed
JP-S59137408-A OINTMENT TAISHO PHARMACEUT CO LTD 1984-08-07 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012051-A1 EXTERNAL PREPARATION CYP4A11, CYP46A1, CYP11B2 NR3C2 55/4885PGR 2297/4885NR3C1 556/4885
US-20070287689-A1 Therapeutic And/Or Preventive Agents For Chronic Skin Diseases PDE4A, PDE3B, PDE2A NR3C2 30/4885PGR 1575/4885NR3C1 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.